Efficacy and safety analysis of CAR-T cell salvage therapy in relapsed/refractory diffuse large B-cell lymphoma after failure of bispecific antibody treatment
Retrospective analysis shows CAR-T therapy improves outcomes in relapsed/refractory DLBCL after bispecific antibody treatment failure, suggesting a promising salvage option.
Key Points
The study aims to evaluate the efficacy and safety of CAR-T cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma who failed bispecific antibody treatment.
Retrospective enrollment of 12 patients with R/R DLBCL after BsAb failure.
Clinical data evaluation to assess efficacy and safety outcomes.
Follow-up assessment was conducted with a median duration of 9.3 months.
100% overall response rate, with 50% achieving complete response and 50% partial response.
12-month progression-free survival rate is estimated at 54.5%.
Common toxicities included cytokine release syndrome (83.3%) and grade ≥ 3 neutropenia (100%).